Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allarity Therapeutics Inc ALLR

Healthcare Biotechnology
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the... see more

Recent & Breaking News (NDAQ:ALLR)

Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering

GlobeNewswire April 19, 2023

This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' Trial

Accesswire April 17, 2023

Abstract Evaluating Allarity's DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting

GlobeNewswire April 11, 2023

Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies

GlobeNewswire March 28, 2023

Allarity Therapeutics Announces Reverse Stock Split of Common Stock

GlobeNewswire March 24, 2023

Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors

GlobeNewswire March 20, 2023

Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

GlobeNewswire January 20, 2023

Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date

GlobeNewswire December 1, 2022

Allarity Therapeutics Reports Third Quarter 2022 Financial Results

GlobeNewswire November 15, 2022

Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders

GlobeNewswire November 7, 2022

Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform

TheNewsWire October 18, 2022

Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements

GlobeNewswire October 11, 2022

Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors

GlobeNewswire September 26, 2022

Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference

GlobeNewswire September 16, 2022

Allarity Therapeutics Announces Appointment of New Auditor

GlobeNewswire September 12, 2022

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

GlobeNewswire August 26, 2022

Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies

GlobeNewswire August 2, 2022

Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D.

GlobeNewswire July 11, 2022

Allarity Therapeutics Announces Executive Leadership Transition

GlobeNewswire June 29, 2022

Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.

GlobeNewswire June 15, 2022